

**PRESS RELEASE**



**For Further Information Contact:**  
Patrick J. Muraca, President and CEO

**Nuclea Biotechnologies, LLC**  
105 South Street  
Pittsfield, MA 01201  
413-749-7405 (Ph)  
413-445-9930 (Fax)

Clark University Campus  
Lasry Center for Bioscience  
Sackler Sciences Center  
950 Main Street  
Worcester, MA 01601  
Email: [pr@nucleabio.com](mailto:pr@nucleabio.com)  
[www.nucleabio.com](http://www.nucleabio.com)

**FOR IMMEDIATE RELEASE**

**NUCLEA BIOTECHNOLOGIES, LLC ANNOUNCES TODAY THE CLOSING OF A  
\$2.5 MILLION DOLLAR PRIVATE PLACEMENT**

**Pittsfield and Worcester, MA.....April 16<sup>th</sup>, 2010.....Nuclea Biotechnologies, LLC** announced today the closing of a \$2.5 Million Dollar Private Placement. This offering is for Preferred Units of the Company. The Company had a Private Placement closing upon receiving commitments for \$2.5 million dollars of Preferred Units, prior to deducting placement agent fees, legal fees and other offering expenses payable by the Company.

The proceeds will be used to finance the commercialization of the Company's diagnostic tests, the development of additional diagnostic clinical trials, to expand the Company's collaboration with the Dana Farber Cancer Institute's Center for Molecular Oncologic Pathology and to expand operational capabilities at our Pittsfield, MA location

"We are very pleased with this Private Placement closing of \$2.5 million dollars" states Patrick Muraca, President and CEO. "This infusion of capital allows Nuclea to fully develop our diagnostic strategy and to finance a new comprehensive collaboration with Dana Farber Cancer Institute.

Total amount raised in two private placements within the past 12 months totals \$5.9 Million Dollars.

**Nuclea Biotechnologies, LLC** is a Delaware limited liability company based in Pittsfield and Worcester, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories ("NDL") which has developed and is commercializing five unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers ("NBM") which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics ("NBT") which has developed several therapeutics now in animal trials.

